Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

BeyondMD vs Emerge Weight Loss

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.6

BeyondMD

Best for mainstream telehealth GLP-1 access

Starting at $139/mo

CompoundedSemaglutideTirzepatide
Visit BeyondMD
7.6

Emerge Weight Loss

Best for patients committed to tirzepatide as their drug of choice

Starting at $299/mo

CompoundedTirzepatideTelehealthPhysician supervised
Visit Emerge Weight Loss

Side-by-Side Comparison

FeatureBeyondMDEmerge Weight Loss
Overall Score7.6/107.6/10
Starting Price$139/mo$299/mo
Customer Rating
Features3 features4 features
States Available5050
Compounded✓ Yes✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

BeyondMD

Pros

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Cons

  • Limited public information on program details

Emerge Weight Loss

Pros

  • Tirzepatide-focused (largest effect-size compounded GLP-1)
  • Wide dose range available
  • Physician-supervised telemedicine model

Cons

  • No semaglutide option — limits flexibility if tirzepatide tolerability is poor
  • Less brand recognition than Henry Meds, Mochi, or SkinnyRx

Our Verdict

Both BeyondMD and Emerge Weight Loss score equally well overall — the right choice depends on your priorities. Choose BeyondMD if you want mainstream telehealth GLP-1 access, or Emerge Weight Loss if patients committed to tirzepatide as their drug of choice matters most to you.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.